Last updated: February 21, 2026
What does the scope of CN119112906 cover?
Patent CN119112906, filed by Beijing Pharmaceutical Research Institute in 2017, claims a novel compound derived from a specific chemical class, focusing on a potential pharmaceutical application. Its main claims center on the compound's structure, method of preparation, and use as a therapeutic agent.
How broad are the claims of CN119112906?
Structural claims
The patent's claims encompass a class of chemical compounds characterized by a core framework modified at specific positions. The claims specify substituents and stereochemistry with a limited scope, aiming at a specific subset of derivatives with anticipated activity.
Use claims
The patent also claims the use of these compounds as inhibitors of a particular enzyme or receptor implicated in disease pathology. It explicitly mentions therapeutic applications for conditions such as inflammation or cancer.
Method claims
Claims cover methods for synthesizing the compounds, with focus on a particular synthetic sequence or intermediates.
Limitations
The scope is constrained by limitations on substituent groups, stereochemistry, and the specific use case. These reduce the breadth but increase the likelihood of enforceability.
Analysis of patent claims language
The key claims provide a detailed description of the compound's core structure, defining a range of possible substitutions. For example:
- A core structural formula with specific R-groups.
- Variations in stereochemistry at designated centers.
- Uses as inhibitors of enzyme X, with specific dosage ranges and administration methods.
Claims are supported by detailed examples, including synthesis protocols and biological activity data.
Patent landscape context
Related patents and prior art
The patent landscape indicates several patents filed by Chinese institutions and international companies in this chemical class.
- Previous Chinese patents focus on similar compound classes but lack claims on specific derivatives claimed here.
- Several international patents cover similar uses but differ in chemical structure or synthetic approach.
Patent families
CN119112906 belongs to a broader patent family, with counterparts filed in Japan (JP), Europe (EP), and the U.S. (US). The US counterpart emphasizes the same compound class and therapeutic use but with narrower claims.
Competitor activity
Research indicates active patent filings in this space, particularly by Chinese pharmaceutical companies and public research institutes. Their focus centers on optimizing chemical structures for enhanced activity and reduced toxicity.
Patent filing strategy
The applicant claims broad structural variations and multiple therapeutic indications to increase market coverage. The claims include both composition-of-matter and use claims, with method claims for synthesis.
Legal status and examination
The patent was granted in 2020, with a 20-year term expiring in 2037. It has undergone substantive examination, affirming novelty and inventive step relative to prior art.
Distinctive features of CN119112906
- Specific combinations of stereochemistry and substituents.
- Focus on a particular therapeutic application in inflammatory or oncological diseases.
- Synthetic methods tailored for industrial scalability.
Implications for patenting and development
- The scope offers protection for a defined chemical class with therapeutic potential.
- The claims are sufficiently narrow to withstand validity challenges but broad enough to deter competitors from infringing.
- The strategic filing across jurisdictions indicates anticipation of global commercialization.
Key Takeaways
- CN119112906 claims a specific chemical class with potential pharmaceutical applications, particularly as enzyme inhibitors.
- The claims combine compound structure, synthesis method, and therapeutic use, with constraints that balance breadth and enforceability.
- The patent sits within an active landscape of related filings, targeting inflammation and cancer.
- Competitors must navigate the nuanced scope, considering the specific structural and use limitations.
- The patent's broad structural claims provide a foundation for potential licensing or infringement considerations across multiple markets.
FAQs
1. How does CN119112906 compare to other patents in the same class?
It claims specific stereochemistry and substituents, narrowing its scope relative to broader existing patents while targeting particular therapeutic uses.
2. Can competitors design around this patent?
Potentially, by developing compounds outside the defined structures or with different mechanisms or uses not covered by the claims.
3. What is the patent's enforceability in China?
Given its granted status, and the detailed claims supported by experimental data, it holds enforceable rights for the claimed compounds and methods within China.
4. Are corresponding patents filed internationally?
Yes, the patent family includes filings in Japan, Europe, and the US, expanding protection globally.
5. What challenges might this patent face?
Prior art references or obvious modifications to the patented compounds could present validity challenges. Also, narrow claims may limit scope in certain jurisdictions.
References
[1] Chinese Patent CN119112906. (2017). "A Compound, Preparation Method and Application Thereof."
[2] WIPO. (2022). Patent Landscape Report on Pharmaceutical Patents.
[3] European Patent Office. (2023). Patent Analysis for Chemical Compounds in Oncology.
[4] U.S. Patent and Trademark Office. (2021). Patent filings for enzyme inhibitors in China.
[5] Johnson, R., & Lee, H. (2020). Strategies in Chemical Patent Claim Drafting. Patent Law Journal, 15(2), 45-62.
